Sodium balance in cirrhosis

Sodium in Health and Disease

Volumn , Issue , 2007, Pages 317-332

  Cárdenas, Andrés ^a   Ginès, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891402229     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (83)

1. Arroyo V, Ginès P, Planas R, Rodés J. Pathogenesis, diagnosis and treatment of ascites in cirrhosis. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J, eds. Oxford Textbook of Clinical Hepatology. 2nd ed. Oxford: Oxford University Press, 1999: 697-732.
2. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8.
3. Jiménez W, Clària J, Arroyo V. Experimental cirrhosis and pathogenesis of ascites formation in chronic liver disease. In: Holstege A, Hahn EG, Scholmerich J, eds. Portal Hypertension. Dordrecht: Kluwer Academic, 1995: 15-25.
4. Clària J, Jiménez W. Experimental models of cirrhosis and ascites. In: Ginés P, Arroyo V, Rodes J, Schrier R, eds. Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Oxford: Blackwell Publishing, 2005: 215-26.
5. D’Amico G, Luca A, Morabito A, Miraglia R, D’Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129: 1282-93.
6. Cárdenas A, Bataller R, Arroyo V. Mechanisms of ascites formation. Clin Liver Dis 2000; 4: 447-65.
7. Menon K, Kamath P. Regional and systemic hemodynamic disturbances in cirrhosis. Clin Liver Dis 2001; 5: 617-27.
8. Guevara M, Bru C, Ginès P, et al. Increased cerebral vascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28: 39-44.
9. Maroto A, Ginès P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17: 788-93.
10. Ruiz del Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-47.
11. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50: 571-81.
12. Titós E, Clària J, Bataller R, et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 2000; 119: 794-805.
13. Graupera M, Garcia-Pagan JC, Abraldes JG, et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003; 37: 172-81.
14. Bataller R, Sancho-Bru P, Ginès P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125: 117-25.
15. Wiest R, Groszmann R. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478-91.
16. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114: 344-51.
17. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-7.
18. Wiest R, Groszmann R. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19: 411-26.
19. Moller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001; 61: 421-9.
20. Asbert M, Jiménez W, Gaya J, et al. Assessment of the renin-angiotensin system in cirrhotic patients. Comparison between plasma renin activity and direct measurement of immunoreactive renin. J Hepatol 1992; 15: 179-83.
21. Bernardi M, Domenicali M. The renin-angiotensin system in cirrhosis. In: Ginès P, Arroyo V, Rodes J, Schrier R, eds. Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Oxford: Blackwell Publishing, 2005: 43-53.
22. Arroyo V, Bosch J, Mauri M, et al. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981; 11: 221-9.
23. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-9.
24. Dudley F, Esler M. The sympathetic nervous system in cirrhosis. In: Ginès P, Arroyo V, Rodes J, Schrier R, eds. Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Oxford: Blackwell Publishing, 2005: 54-72.
25. Henriksen JH, Ring-Larsen H, Christensen NJ. Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. Gut 1987; 28: 1637-42.
26. MacGilchrist AJ, Howes LG, Hawksby C, et al. Plasma noradrenaline in cirrhosis: a study of kinetics and temporal relationship to ascites formation. Eur J Clin Invest 1991; 21: 238-43.
27. Esler M, Dudley F, Jennings G, et al. Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis. Ann Intern Med 1992; 116: 446-55.
28. Henriksen JH, Ring-Larsen H, Kanstrup IL, et al. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis. Gut 1984; 25: 1034-43.
29. Pérez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26: 72-80.
30. Laffi G, La Villa G, Pinzani M, et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997; 17: 530-48.
31. Hansen PB, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Renal Physiol 2003; 285: F590-9.
32. Milani L, Merkel C, Gatta A. Renal effect of aminophylline in hepatic cirrhosis. Eur J Clin Pharmacol 1983; 24: 757-60.
33. Stanley AJ, Forrest EH, Dabos K, Bouchier IAD, Hayes PC. Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites. Gastroenterology 1998; 115: 406-11.
34. Llach J, Ginès P, Arroyo V, et al. Effect of dipyridamole on kidney function in cirrhosis. Hepatology 1993; 17: 59-64.
35. Blantz RC, Deng A, Lortie M, et al. The complex role of nitric oxide in the regulation of glomerular ultrafiltration. Kidney Int 2002; 61: 782-5.
36. Clària J, Jiménez W, Ros J, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 1992; 15: 343-9.
37. Ros J, Clària J, Jiménez W, et al. Role of nitric acid and prostaglandin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995; 22: 915-20.
38. Jiménez W, Martínez-Pardo A, Arroyo V, et al. Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology 1985; 5: 245-50.
39. Fernandez-Llama P, Ginès P, Schrier RW. Pathogenesis of sodium retention in cirrhosis: the arterial vasodilation hypothesis of ascites formation. In: Ginès P, Arroyo V, Rodes J, Schrier R, eds. Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Oxford: Blackwell Publishing, 2005: 201-14.
40. Bernardi M, Laffi G, Salvagnini M, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993; 13: 156-62.
41. Ginès P, Fernández-Esparrach G, Arroyo V, et al. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17: 175-89.
42. La Villa G, Salmerón JM, Arroyo V, et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 1992; 102: 2114-9.
43. Wong F, Liu P, Allidina Y, et al. Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. Gastroenterology 1995; 108: 1820-7.
44. Bernardi M. Renal sodium retention in preascitic cirrhosis: expanding knowledge, enduring uncertainties. Hepatology 2002; 35: 1544-7.
45. Bernardi M, Trevisani F, Santini C, et al. Aldosterone related blood volume expansion in cirrhosis before and after the early phase of ascites formation. Gut 1983; 24: 761-6.
46. Caregaro L, Lauro S, Angeli P, et al. Renal water and sodium handling in compensated liver cirrhosis: mechanism of the impaired natriuresis after saline loading. Eur J Clin Invest 1985; 15: 360-5.
47. Schrier RW. Peripheral arterial vasodilation in cirrhosis and impaired mineralocorticoid escape. Gastroenterology 1992; 102: 2165-8.
48. Wang XY, Masilamani S, Nielsen J, et al. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest 2001; 108: 215-22.
49. Bernardi M, Di Marco C, Trevisani F, et al. Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 1993; 105: 188-93.
50. Wong F, Liu P, Blendis L. The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology 2002; 35: 1449-58.
51. Angeli P, Gatta A, Caregaro L, et al. Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur J Clin Invest 1990; 20: 111-7.
52. López-Novoa JM, Rengel MA, Rodicio JL, et al. A micropuncture study of salt and water retention in chronic experimental cirrhosis. Am J Physiol 1977; 232: F315.
53. Fernández-Llama P, Ageloff S, Fernández-Varo G, et al. Sodium retention in cirrhotic rats is associated with increased renal abundance of sodium transporter proteins. Kidney Int 2005; 67: 622.
54. Epstein M, Ramachandran M, DeNunzio AG. Interrelationship of renal sodium and phosphate handling in cirrhosis. Miner Electrolyte Metab 1982; 7: 305.
55. Diez J, Simon MA, Anton F, et al. Tubular sodium handling in cirrhotic patients with ascites analysed by the renal lithium clearance method. Eur J Clin Invest 1990; 20: 266.
56. Gatta A, Angeli P, Caregaro L, et al. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 1991; 14: 231.
57. Angeli P, Gatta A. Medical treatment of ascites in cirrhosis. In: Ginès P, Arroyo V, Rodes J, Schrier R, eds. Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Oxford: Blackwell Publishing, 2005: 227-40.
58. Girgrah N, Liu P, Collier J, et al. Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis. Gut 2000; 46: 114-20.
59. Helmy A, Jalan R, Newby DE, et al. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000; 118: 565-72.
60. Trevisani F, Bernardi M, DePalma R, et al. Circadian variation in renal sodium and potassium handling in cirrhosis. The role of aldosterone, cortisol, sympathoadrenergic tone, and intratubular factors. Gastroenterology 1989; 96: 1187-98.
61. Pérez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of furosemide versus spironolactone in patients with liver cirrhosis and ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983; 84: 961-8.
62. Yang YY, Lin HC, Lee WC, et al. One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. J Gastroenterol 2002; 37: 194-9.
63. Esler M, Kaye D. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J Auton Nerv Syst 1998; 72: 210-9.
64. SalòJ, Ginés A, Anibarro L, et al. Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone and norepinephrine levels. Hepatology 1995; 22: 479-87.
65. Ming Z, Smyth DD, Lautt WW. Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: role of adenosine. Hepatology 2002; 35: 167-75.
66. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997; 40: 664-70.
67. Arroyo V, Rodés J, Gutiérrez-Lizarraga MA, Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976; 21: 249-56.
68. Porcel A, Diaz F, Rendon P, et al. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162: 323-8.
69. Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 46-52.
70. Ishikawa S, Schrier RW. Pathogenesis of hyponatremia: the role of arginine vasopressin. In: Ginès P, Arroyo V, Rodes J, Schrier R, eds. Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Oxford: Blackwell Publishing, 2005: 305-14.
71. Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, Mattera R. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998; 449: 251-76.
72. Verbalis J. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002; 29: 1-9.
73. Kwon TH, Hager H, Nejsum LN, Andersen ML, Frokiaer J, Nielsen S. Physiology and pathophysiology of renal aquaporins. Semin Nephrol 2001; 21: 231-8.
74. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002; 82: 205-44.
75. Cárdenas A, Ginés P. Treatment of hyponatremia in cirrhosis. In: Arroyo V, Navasa M, Foros X, Bataller R, Sanchez-Fueyo A, Rodes J, eds. Update in Treatment of Liver Disease. Barcelona: Ars Medica, 2005: 93-102.
76. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182-91.
77. Gerbes AL, Gulberg V, Ginès P, et al. VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933-9.
78. Afdhal N, Cardenas A, Guevara M, et al. For the SALT Study Investigators. Randomized, placebo-controlled trial of tolvaptan, a novel V2-receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis. Hepatology 2005; 42: LB19A.
79. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 1819-27.
80. Guevara M, Ortega R, Ginès P, Rodés J. Pathogenesis of renal vasoconstriction in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Oxford: Blackwell, 2005: 329-40.
81. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
82. Platt JF, Ellis J, Rubin JM, et al. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20: 362-9.
83. Maroto A, Ginès A, Saló J, et al. Diagnosis of functional renal failure of cirrhosis by Doppler sonography. Prognostic value of resistive index. Hepatology 1994; 20: 839-44.